Alaska Fund acquires a taste for big biotech startups

The $50 billion Alaska Permanent Fund, which handles the state's oil wealth, has invested $280 million in three biotechs: Juno ($JUNO), Denali and Codiak. And a story from Bloomberg's Doni Bloomfield notes that it works in the belief that patience is a competitive virtue when it comes to the life sciences. Interesting fact: All three startups it helped foster bear names linked to Alaska, which is far from the beaten track in biotech. Story

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.